Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.”

The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic crisis.”

The continued upswing in neutraceutical sales plays into the hands of Cardium Therapeutics (NYSE MKT: CXM) and its growing portfolio of neutraceuticals that complement its health science and regenerative medicine pipeline.

A recent article by leading investor relations firm MissionIR discusses the benefits of Cardium’s recent acquisition of To Go Brands in this burgeoning market.

Cardium Therapeutics, Inc. (CXM) Acquisition of To Go Brands Further Taps Growing Supplements Market

The recent acquisition by Cardium Therapeutics, a health sciences and regenerative medicine company, of To Go Brands, a private California-based nutraceutical company, is in line with Cardium’s strategy of accelerating the growth and development of their own MedPodium health supplements platform. MedPodium is Cardium’s portfolio of science-based nutraceuticals, metabolics, and aesthetics, designed to promote healthy lifestyle interests such as enhancing energy, cognition, mood, sleep, weight management, fitness, and aesthetics. The acquisition provides Cardium with a greatly expanded marketing and distribution network, together with an established line of compatible products.

To Go Brands has developed and sells 25 health supplement related products, including 100% natural antioxidant rich drink mixes with organic ingredients, in various forms for easy use, along with capsule-based dietary supplements. Their products are sold online, and in a wide range of retail stores, such as Kroger, Whole Foods, GNC, Hi-Health, Vitamin World, and many others. To Go Brands sales for the first 6 months of 2012 totaled $1.7 million.

The acquisition also brings Cardium an experienced management team with key contacts, and a successful record of developing and taking to market new health products through different channels. The agreement calls for To Go Brands to coordinate Cardium’s MedPodium line, using To Go Brands’ established logistics and distribution capabilities. They will also work with Cardium’s strategic investment in SourceOne Global Partners, a leading supplier of science-based ingredients and proprietary formulas to the national supplement and functional food and beverage industries.

Cardium CEO, Christopher J. Reinhard, commented on the growth of the supplements market: “According to a new industry report, U.S. supplement sales are estimated to total $11.5 billion in 2012 and are projected to reach $15.5 billion by 2017. The success of products like Five Hour Energy® have shown that the nutraceutical space has the potential to generate billion dollar products without the extensive regulatory and other hurdles biologics and pharmaceuticals face.”

Cardium Therapeutics (CXM) Stock Quote and News:

---

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated two thousand five hundred dollars by Cardium Therapeutics for its efforts in managing the dissemination of public corporate information on its website and to its database of subscribers and across select financial and social media websites. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.